Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment

• References

• 1 Jauch EC, Saver JL, Adams Jr. HP. et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke J Cereb Circ 2013; 44: 870-947.
• 2 Laux V, Perzborn E, Kubitza D. et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb He-most 2007; 33: 515-523.
• 3 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
• 4 Product Monograph.. Pradaxa TM, dabigatran et-exilate capsules. Boehringer Ingelheim Canada website. Available at: http://www.boehringer-in/gelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/productmonograph/PradaxaPMEN0513.pdf. Accessed May 16, 2013.
• 5 Garcia D, Barrett YC, Ramacciotti E. et al. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11: 245-252.
• 6 Samama MM, Martinoli J-L, LeFlem L. et al. Assessment of laboratory assays to measure riva-roxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
• 7 Matute MC, Guillán M, García-Caldentey J. et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
• 8 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plas-minogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis Basel Switz 2010; 30: 533-534.
• 9 Bayer Pharma AG: Xarelto^® (rivaroxaban) summary of product characteristics. 2013 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product-Information/human/000944/WC500057108.pdf. Accessed May 16, 2013.
• 10 Samama MM, Contant G, Spiro TE. et al. Laboratory assessment of rivaroxaban: a review. Thromb J 2013; 11: 11.
• 11 Samama MM, Contant G, Spiro TE. et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
• 12 Steiner T, Böhm M, Dichgans M. et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.